Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis.
Key claim: Dihomo-gamma-linolenic acid (DGLA) depletion allows damaged cells to persist in senescence, and exogenous DGLA supplementation selectively triggers ferroptotic clearance of senescent cells, improving functional outcomes in aged mice.
Abstract
When subject to damage or stress, cells develop responses in order to maintain tissue homeostasis. Two such responses are ferroptosis and cellular senescence, but how cells decide between these outcomes remains unclear. Here, we show that senescent cells increase import and membrane levels of multiple polyunsaturated fatty acids (PUFAs), but a specific intermediate PUFA, dihomo-gamma-linolenic acid (DGLA, 20:3ω-6), is reduced. Exogenous repletion of DGLA instead results in cell death by ferroptosis. Senescent cells manifest additional features associated with ferroptosis, including labile iron and expression of lipoxygenases as well as low-level membrane peroxidation. Oral DGLA supplementation lowers markers of senescence in aged mice and improves age-related functional outcomes. Finally, obese humans with lowered DGLA desaturation rates have lower markers of adipose tissue senescence. Together, our data implicate shifts in PUFA metabolism as a driver of decisions between senescence and ferroptosis.
Why this matters
This cell and aged-mouse study [animal-model] places fatty-acid metabolism upstream of whether damaged cells persist in senescence or undergo ferroptosis, extending the causal picture beyond senescence entry to metabolic control of cell survival. Reported functional improvements with oral DGLA [animal-model] introduce a ferroptosis-based senolytic candidate, not an established human anti-aging supplement; human efficacy, tissue selectivity, and safety remain unestablished. Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.